
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Click the title above to open the Pharmaceutical Technology Partnering for Bio/Pharma Success 2020 in an interactive PDF format.
almost 7 years ago
Building a Business Case for Quality Management Transformationalmost 7 years ago
Building Strategic Relationships with CROsalmost 7 years ago
Pharma Contract Market Updatealmost 7 years ago
Digitalization: A CDMO’s Perspectivealmost 7 years ago
Sourcing Success in Cell and Gene Therapy Developmentalmost 7 years ago
More Capacity and Technology Translate to More Optionsalmost 7 years ago
Growth in Biologics Market Inspires Outsourcing




